Vascular Parkinsonism (VP) is a rare form of parkinsonism due to impairment of the central nervous system caused by damage to its blood supply. The primary symptom is tremor, which often occurs in the hands and legs, but can also affect other areas of the body. VP is caused by a variety of different conditions that block or damage small arteries, veins, or capillaries that supply the brain. This decrease in brain perfusion (blood flow) can cause a disruption of communication between neurons and, consequently, a decline in movement coordination and mobility. In addition, a decrease in dopamine, a neurochemical that helps regulate movement, may be associated with VP. Treatment of VP typically involves addressing the underlying cause, which may include anticoagulants to prevent disorders related to clot formation, or drugs to reduce inflammation and prevent clots from forming and blocking blood vessels. Physical therapy and occupational therapy, as well as drugs that increase dopamine levels, may also be used in the treatment of VP. Additionally, lifestyle modifications like stress management, exercise, and diet modification may help improve symptoms of VP. Research has shown that regular exercise can help reduce tremor and spacing out of activities may reduce the intensity of symptoms. Additionally, certain nutritional modifications like avoiding tyramines (naturally occurring amines found in some foods) may help reduce symptom severity. Overall, VP is a rare but serious disorder that can be managed with a combination of treatments. While VP may have a significant physical and psychological impact on patients, early diagnosis and a tailored treatment plan can enable patients to lead an independent and fulfilling life.
Title : Perception and individuality in patient cases identifying the ongoing evolution of Myalgic Encephalomyelitis/Chronic Fatigue Syndrome (ME/CFS)
Ken Ware, NeuroPhysics Therapy Institute, Australia
Title : Narrative medicine: A communication therapy for the communication disorder of Functional Seizures (FS) [also known as Psychogenic Non-Epileptic Seizures (PNES)]
Robert B Slocum, University of Kentucky HealthCare, United States
Title : Personalized and Precision Medicine (PPM), as a unique healthcare model through biodesign-driven biotech and biopharma, translational applications, and neurology-related biomarketing to secure human healthcare and biosafety
Sergey Victorovich Suchkov, N. D. Zelinskii Institute for Organic Chemistry of the Russian Academy of Sciences, Russian Federation
Title : Neuro sensorium
Luiz Moutinho, University of Suffolk, United Kingdom
Title : GBF1 inhibition reduces amyloid-beta levels in viable human postmortem Alzheimer's disease cortical explant and cortical organoid models
Sean J Miller, Yale School of Medicine, United States
Title : Traumatic Spinal Cord Injuries (tSCI) - Are the radiologically based “advances” in the management of the injured spine evidence-based?
W S El Masri, Keele University, United Kingdom